Currently used as part of the standard of care in estrogen receptor-positive HER2-negative advanced breast cancer, CDK4 and CDK6 inhibitors function by preventing complex formation with D-cyclins leading to tumor suppressor retinoblastoma protein (Rb) dephosphorylation and subsequent cell cycle arrest. This evidence concerns the gene CDK4 and breast cancer.